Knight Therapeutics Inc T.GUD

Nothing unusual ...

[MrMugsy]

retail investors drove the shares up, expecting a pop after the release.
didn't get the pop.
had to sell because they had no intention of holding.

now the more serious investor comes in - company also buys back shares.  
same old game until we remove a lot of those free shares.

until more serious buy-and-hold investors come in ... we will wait.  

The company has to get a little bigger on the operational side to drown out the effects of the financing side.  I think that's what it will take with institutional investors.  We're just not there yet and it's hard to tell when that happens.

-------------

Key - more ROW drugs !!!!!

[EbbFlow88]

I agree. The accumulation game is the way to go as you've mentioned countless times. The operational trend is our friend but the market is more and more short term oriented.  Analysts have downgraded the stock but there are big buyers coming in above 5$ * Raymond James’ David Novak to $7.50 from $8.50 with an “outperform” rating. “Considering the ongoing valuation deflation plaguing

[longrun86]

It was a soft quarter and 2022 revenue guidance was lower than analyst expectations. I appreciate their conservatism in projections and my view is that there are a lot of opportunities for them to deploy capital over the next 12 to 24 months at higher rates of return than the funds they are ion today that are more meaningful to the business model. My view is that the ROW platform should be 3x to

[MrMugsy]

Yes - well said ... ROW drugs will add - from small/big pharma Branded Generics will provide opportunity. Bolt-on acquisitions - can play a role - and - with boots on the ground ... could come from anywhere in Latin America. Bolt-on acquisitions from other new ROW geographies outside North/South America. For now - I still think we have lots in the hopper (early days) ... even EXELON and